ANNAPOLIS, Md., Feb. 23 (UPI) -- PharmAthene Inc. received new funding to continue anthrax vaccine development supporting the U.S. Strategic National Stockpile.
U.S. company PharmAthene received the contract modification from the U.S. Health and Human Services Department. As part of the new $78.4 million in additional funding, PharmAthene will continue development of the SparVax anthrax vaccine.
The contract modification, awarded through the Biomedical Advanced Research and Development Authority, is expected to provide the Strategic National Stockpile with protective antigen anthrax vaccine that can be deployed in case of an emergency event.
"We are pleased to be awarded additional development funding for our SparVax anthrax vaccine program, which may offer a promising improved alternative to existing anthrax vaccine options," David Wright, PharmAthene president and chief executive officer, said in a statement.
"There is widespread acknowledgment among various government agencies that the United States must develop and stockpile a second generation anthrax vaccine employing modern vaccine technology that offers the potential for improved safety, convenience and enhanced cost effectiveness."